Chief Legal Officer · Definium Therapeutics, Inc. (DFTX)

Mark Sullivan

A named executive officer of Definium Therapeutics in every fiscal year CompBrief holds from FY2023 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$1,161,107

Salary $439,750Stock awards $0

FY2023: $1,080,394

4th of 4 named executive officers at Definium Therapeutics by FY2024 total.

4 named officers on file for Definium Therapeutics, FY2024

Mark Sullivan’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 1 equity grant, each cited to its filing
  • DFTX’s disclosed peer group of 19 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Definium Therapeutics’s whole pay program stands against its peers

  • Definium Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on DFTX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 23, 2025 (DEF 14A).

Free

Get Mark Sullivan’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Mark Sullivan compensation by year

Definium Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Definium Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023FY2024
Salary$308,167$439,750
Bonus$0$0
Stock awards$596,000$0
Option awards$0$522,500
Non-equity incentive$163,400$184,288
Pension and deferred compensation$0$0
All other$12,827$14,569
Total$1,080,394$1,161,107

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Definium Therapeutics, Inc. DEF 14A filed April 23, 2025, accession 0001104659-25-038010, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Definium Therapeutics, Inc. filed document, accession 0001104659-25-038010. Every figure is read from that document and cited to the page and table it appears in. Filed April 23, 2025.

$1.1M
$1.2M
FY23
FY24
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU125,000$870,000—
Option98,959—$4.98

Per the Outstanding Equity Awards at Fiscal Year-End table in Definium Therapeutics, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Definium Therapeutics’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Robert BarrowChief Executive Officer$2,669,010
Daniel KarlinChief Medical Officer$1,330,319
Schond GreenwayFormer Chief Financial Officer$1,196,149
Mark Sullivan · this pageChief Legal Officer$1,161,107

The full Definium Therapeutics compensation record

free company brief

This page is one person within Definium Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Definium Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Definium Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Mark Sullivan's compensation dossier · One-time report. No refunds.